Aimmune Therapeutics Inc AIMT:NASDAQ

Last Price$24.21NASDAQ Previous Close - Last Trade as of 4:00PM ET 10/14/19

Today's Change-0.34(1.38%)
Bid (Size)$22.69 (15)
Ask (Size)$25.99 (1)
Day Low / High$24.00 - 25.03
Volume787.2 K

Analyst Actions: Credit Suisse Cuts Aimmune Therapeutics PT to $30 from $36, Assumes Coverage at Outperform on Peanut Allergy Drug - Stock Up 3%

2:04PM ET 5/21/2019 MT Newswires
Credit Suisse has cut its price target on Aimmune Therapeutics (AIMT) to $30 from $36 while assuming its outperform rating, betting on its current leadership in the peanut allergy treatment space with its late-state asset AR101 and its being a possible takeover target. The company has no commercial business income currently.

"Beginning next year, we expect AR101 to generate revenue for the company with unadjusted potential sales of $1.2B by 2024, vs. no product revenues currently," Credit Suisse said in a note.

"From an M&A perspective, we believe that Aimmune is an acquisition target from a position of strength, as it has an asset that is likely to be approved near-term," the analyst said. "A company could acquire prior to approval and shape the commercial trajectory of the asset."

Price: 20.24, Change: +0.59, Percent Change: +3.00